Onyx Pharmaceuticals, Inc.
http://www.onyx-pharm.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Onyx Pharmaceuticals, Inc.
Roche Looks To Defy The Odds In Parkinson’s Study
Others have tried and failed to target α-synuclein in Parkinson’s disease, but Roche hopes a Phase II study could deliver success later this year.
Marching On: Eight Novel Agents Among March Goal Dates For US FDA
Crowded calendar could bring to an end the slow start for novel approvals in 2024, as decisions come due for Lilly’s donanemab, Merck’s sotatercept, Regeneron’s odronextamab and more.
OTC Naloxone Pioneer Emergent BioSolutions Puts Papa At Helm As It Navigates Strategy Shift
Like his previous move, Papa joins a pharma firm making a significant organizational shift to cut costs and increase revenues after extended period of higher spending and slowing income.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Company Information
- Other Names / Subsidiaries
-
- Proteolix, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice